EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer by Tang, Su-Ni et al.
EGCG Enhances the Therapeutic Potential of
Gemcitabine and CP690550 by Inhibiting STAT3
Signaling Pathway in Human Pancreatic Cancer
Su-Ni Tang
1, Junsheng Fu
2, Sharmila Shankar
2, Rakesh K. Srivastava
1*
1Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City,
Kansas, United States of America, 2Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center,
Kansas City, Kansas, United States of America
Abstract
Background: Signal Transducer and Activator of Transcription 3 (STAT3) is an oncogene, which promotes cell survival,
proliferation, motility and progression in cancer cells. Targeting STAT3 signaling may lead to the development of novel
therapeutic approaches for human cancers. Here, we examined the effects of epigallocathechin gallate (EGCG) on STAT3
signaling in pancreatic cancer cells, and assessed the therapeutic potential of EGCG with gemcitabine or JAK3 inhibitor
CP690550 (Tasocitinib) for the treatment and/or prevention of pancreatic cancer.
Methodology/Principal Findings: Cell viability and apoptosis were measured by XTT assay and TUNEL staining,
respectively. Gene and protein expressions were measured by qRT-PCR and Western blot analysis, respectively. The results
revealed that EGCG inhibited the expression of phospho and total JAK3 and STAT3, STAT3 transcription and activation, and
the expression of STAT3-regulated genes, resulting in the inhibition of cell motility, migration and invasion, and the
induction of caspase-3 and PARP cleavage. The inhibition of STAT3 enhanced the inhibitory effects of EGCG on cell motility
and viability. Additionally, gemcitabine and CP690550 alone inhibited STAT3 target genes and synergized with EGCG to
inhibit cell viability and induce apoptosis in pancreatic cancer cells.
Conclusions/Significance: Overall, these results suggest that EGCG suppresses the growth, invasion and migration of
pancreatic cancer cells, and induces apoptosis by interfering with the STAT3 signaling pathway. Moreover, EGCG further
enhanced the therapeutic potential of gemcitabine and CP690550 against pancreatic cancer.
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Introduction
Signal transduction and activators of transcription (STAT)
proteins is a family of cytoplasmic transcription factors which are
initially present in inactive forms [1,2]. They are stimulated by the
binding of signaling peptides, such as cytokine, growth factors, and
hormone, which results in dimerization of their cognate receptors
and activation of tyrosine kinases such as Janus kinase (JAK). The
activated tyrosine kinases could subsequently phosphorylate the
cytoplasmic domains of receptors to provide recognition sites for
non-phosphorylated STATs monomers. Once STATs are phos-
phorylated by activated tyrosine kinases after binding, they form
homo or hetero-dimers via their Src-homology 2 (SH2) domain
and rapidly migrate into the nucleus, where the dimers bind to
DNA sequences to active specific gene transcription [1,2].
Numerous experiments have demonstrated that normal physical
functions of STATs are critical in regulating many aspects of
cellular proliferation, differentiation, migration, and survival.
Among all the STAT family members, STAT3 is the most
intimately linked to cell survival and proliferation and tumorigen-
esis [3,4]. It is widely expressed in most tissues and is considered as
a potential oncogene. STAT3 is often constitutively active in many
human cancer cells, including multiple myeloma, glioblastoma,
leukemia, lymphoma, breast cancer, prostate cancer, lung cancer,
and neck cancer [5,6,7]. STAT3 can be activated by multiple
cytokines, including IL-6, IL-11, ciliary neurotrophic factor, and
leukemia inhibitory factor, which all use gp130-type receptors.
Interestingly, STAT3 can contribute to either apoptosis or survival
in different organs and cell types. It can promote the proliferation
in hepatocytes [8], neuron cells [9], and T cells [10], but is
indispensable for the apoptosis in mammary [11] and myeloid cells
[12].
STAT3 is a latent transcription factor that resides in the
cytoplasm. Upon activation by tyrosine phosphorylation, STAT3
dimerizes, translocates to the nucleus and binds to nuclear DNA to
modulate transcription of target genes. STAT3 phosphorylation is
principally mediated through the activation of non-receptor
protein tyrosine kinase family of JAKs, which include many
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Additionally, the STAT3 phosphorylation can also be mediated by
crosstalk with c-Src kinase [13,14,15]. The major phosphorylation
sites in STAT3 include tyrosine and serine residues at positions
Tyr
705 and Ser
727, respectively, located in the transactivation
domain. The activation of STAT3 results in expression of many
target genes required for tumor cell survival (e.g. Bcl-XL, Mcl-1
and survivin), proliferation (e.g. cyclin D1 and c-myc) and
angiogenesis [e.g. vascular endothelial growth factor (VEGF)] as
well as metastasis [16]. Thus, STAT3-signaling pathway has been
a favorite therapeutic target for drug development [17,18].
Gemcitabine (a nucleoside analog) showed more clinical benefit
on pancreatic cancer patients compared with the conventional
medications [19]. Some potent and selective JAK3 inhibitors, e.g.
CP690550, demonstrated significant clinical activity in cancer
[20,21]. CP690550 represents only a starting point in the search
for a safer small molecule immunosuppressant, and that an
isozyme-selective JAK3 inhibitor identified by rational drug design
might be substantially safer. In recent years, many new insights
have been gained into the investigation on a variety of purified
compounds from natural products. For instance, EGCG is the
major catechin from green tea and has been recognized as an
important chemopreventive agent and as modulators of tumor cell
response to chemotherapy [22,23,24]. It has been shown to inhibit
cell proliferation [25], induce apoptosis [26] in tumor cells,
prevent angiogenesis [27], modulate the invasion and migration of
cancers, and interfere with multiple signaling pathways, including
the nuclear factor-kB signaling pathway [28], epidermal growth
factor-mediated pathway [29], insulin-like growth factor-I signal-
ing pathway [30], mitogen-activated protein kinase-dependent
pathway [31], and proteasome degradation pathway [32].
In this paper, we examined the effects of EGCG on STAT3
signaling in human pancreatic cancer cells, and also assessed the
interactive effects of EGCG with gemcitabine or JAK3 inhibitor
CP690550 on their therapeutic potential. We found that EGCG
inhibited the expression of JAK3 and STAT3 (phospho and total),
STAT transcription and activation, and the expression of STAT3-
regulated genes, resulting in the inhibition of cell motility,
migration and invasion, and the induction of caspase-3 and PARP
cleavages. Inhibition of STAT3 by shRNA in pancreatic cancer
Figure 1. Effects of EGCG on pancreatic cancer cells. (A), Transwell migration assay. AsPC-1 and PANC-1 cells were plated in the top chamber of
the transwell and treated with EGCG (0–60 mM) for 24 h. Cells migrated to the lower chambered were fixed with methanol, stained with crystal violet
and counted. Data represent mean 6 SD. * or **=significantly different from respective controls, P,0.05. (B) Matrigel invasion assay. AsPC-1 and
PANC-1 cells were plated onto the Matrigel-coated membrane in the top chamber of the transwell and treated with EGCG (0–60 mM) for 48 h. Cells
invaded to the lower chamber were fixed with methanol, stained with crystal violet and counted. Data represent mean 6 SD. * or **=significantly
different from respective controls, P,0.05. (C), Caspase-3 activity. AsPC-1 and PANC-1 cells were treated with EGCG (0–40 mM) for 48 h, and the
caspase-3 activity was measured as per manufacturer’s instructions (Invitrogen). Data represent mean 6 SD. *=significantly different from respective
controls, P,0.05. (D), AsPC-1 and PANC-1 cells were treated with EGCG (0–60 mM) with or without gemcitabine (0.5 mM) for 48 h. Cells were
harvested and the Western blot analysis was performed to examine the expression of PARP and caspase-3. b-actin was used as a loading control.
PARP antibody recognizes cleaved PARP, and caspase-3 antibody recognizes cleaved/active caspase-3.
doi:10.1371/journal.pone.0031067.g001
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and motility. Our results demonstrate that activation of the
STAT3 signaling pathway is critical for the growth of pancreatic
cancer cells and suggest that EGCG targeting STAT3 signaling
may be a potential therapeutic intervention for pancreatic cancer.
Furthermore, the combination of EGCG with gemcitabine or
CP690550 had additive/synergistic effects on cell viability and
apoptosis.
Materials and Methods
Cell lines and culture conditions
Human pancreatic cancer cell lines AsPC-1 and PANC-1 were
purchased from the American Type Culture Collection (Manassas,
VA), and cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum (Thermo Scientific) and 1% antibiotic-
antimycotic (Invitrogen) at 37uC in a humidified atmosphere of
95% air and 5% CO2.
Cell transfection
STAT3 shRNAs were designed using BLOCK-iT
TM RNAi
Designer (Invitrogen).The accession number was obtained from
the Gene bank. The sequences of STAT3 shRNAs (accession
number: NM_139276) are corresponding to the coding regions
398–416 (59- CCA CTT TGG TGT TTC ATA A-39), 1070–1088
(59-CCCGTCAACAAATTAAGAA-39), 1448–1466 (59-GCC
TCT CTG CAG AAT TCA A-39) and 1935–1953 (59-GGA
CAA TAT CAT TGA CCT T-39) nucleotides. AsPC-1 and
PANC-1 cells were transfected with a mixture of shRNAs using
Lipofetamine 2000 (Invitrogen). After 24 h of transfection, cells
were treated with EGCG. Cells were used for cell viability
detection, scratch assay, qRT-PCR and western blotting.
XTT Assay
Cells (1610
4 in 200 ml culture medium per well) were seeded in
96-well plate (flat bottom), treated with or without drugs and
incubated for various time points at 37uC and 5% CO2. Before the
end of the experiment, 50 ml XTT labeling mixture (final
concentration, 125 mM XTT (sodium 2,3-Bis(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt) and
25 mM PMS (phenazine methosulphate) per well was added and
plates were incubated for further 4 h at 37uC and 5% CO2. The
spectrophotometric absorbance of the sample was measured using
a microtitre plate (ELISA) reader. The wavelength to measure
absorbance of the formazon product was 450 nm, and the
reference wavelength was 650 nm.
Figure 2. EGCG inhibits JAK3/STAT3 pathway in pancreatic cancer. (A), AsPC-1 and PANC-1 cells were treated with EGCG (0–60 mM) for 48 h,
and the expression of STAT3 was measured by q-RT-PCR. Data represent mean 6 SD. * or **=significantly different from respective controls, P,0.05.
(B), AsPC-1 and PANC-1 cells were treated with EGCG (0–60 mM) for 48 h. The expression of STAT3, p-STAT3, JAK3 and p-JAK3 was measured by
Western blot analysis. b-actin was used as a loading control. (C), Expression of STAT3 in AsPC-1 and PANC-1 cells. Cells were treated with EGCG (0–
60 mM) for 48 h. After incubation, the expression of STAT3 was measured by immunoflurescence. DAPI was used to stain nuclei. For better visuality,
the color of DAPI was changed from blue to red. The green color represents the expression of STAT3. Red color=nuclei.
doi:10.1371/journal.pone.0031067.g002
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Cells (3610
4 per well) were seeded in a 96-well plate with 200 ml
culture medium. Approximately 16 h later, cells were treated with
various doses of EGCG. Casapse-3/7 activity was measured as per
manufacturer’s instructions (Invitrogen).
Scratch assay
AsPC-1 scrambled and STAT3 shRNA cells were seeded in 6
well dishes. When all the cultures were 50% confluent, a cross was
marked in the center of each dish using a 10 ml tip. The cells were
washed with PBS and cultured in fresh medium. The scratch
pictures were taken under a fluorescence microscope at 0, 24 and
48 h for the same positions after the cells were treated with EGCG.
Transwell migration assay
To determine the effect of EGCG on cell migration, AsPC-1 and
PANC-1 cells were platedin the top of chamber onto the noncoated
membrane (24-well insert; pore size, 8 mm; Corning Costar) at a
density of 1610
4 cells/well in RPMI medium containing 1% FBS,
andallowedtomigratetowardRPMI medium containing10%FBS
in the lower chamber. EGCG was added to the both chambers to
achieve the concentration of 0, 20, 40, 60 mM, respectively. After
24 h of incubation, cells were fixed with 4% paraformaldehyde and
stained with crystal violet. The migrated cells were counted under a
light microscope (four random fields per well).
Transwell invasion assay
To determine the effect of EGCG on cell invasion, AsPC-1 and
PANC-1 cells were plated in the top of chamber onto the Matrigel
coated membrane (24-well insert; pore size, 8 mm; Corning Costar)
at a density of 1610
4 cells/well in RPMI medium containing 1%
FBS, and allowed to invade toward RPMI medium containing 10%
FBS in the lower chamber. EGCG was added to the both chambers
to achieve the concentration of 0, 20, 40, 60 mM, respectively. After
48 h of incubation non-invaded cells were removed by cotton swab,
andinvaded cellswerefixedwith4%paraformaldehydeandstained
with crystal violet. The invaded cells were counted under a light
microscope (four random fields per well).
Transient transfection and STAT3 reporter
AsPC-1 and PANC-1 cells were cultured in 100 mm dishes and
transfected at 70% confluent with pGreenfire1-STAT3 reporter
plasmid usingLipofetamine 2000 (Invitrogen).After 24 h,cells were
treated with EGCG (0–80 mM). After incubation of 24 h, luciferase
activity was determined using the Dual-Luciferase Reporter Assay
System (Promega), according the manufacturer’s instructions on a
multilabel plate reader (Wallac Victor, Perkin-Elmer).
RNA isolation and real-time RT-PCR
Total RNA was isolated from AsPC-1 and PANC-1 cells using
TRIzol reagent (Invitrogen). RNA concentration was determined
using Nano Drop 2000 Spectrophotometer. cDNA was synthesized
and RT-PCR reactions were performed using SuperScript II
(Invitrogen) according to the manufacturer’s instructions. Real-time
PCR was performed on the Applied Biosystems 7300 Real-time PCR
System, using the following program: 50uCf o r2m i n ,9 5 uCf o r
10 min, and then 40 cycles of 95uC for 15 s and 60uCf o r1m i n .P C R
Figure 3. EGCG inhibits the expression of STAT3-regulated genes. (A), STAT3 activity. AsPC-1 and PANC-1 cells were transfected with
pGreenfire1-STAT3 reporter plasmid. Cells were treated with EGCG (0–80 mM). After incubation of 24 hours, luciferase activity was determined using
the Dual-Luciferase Reporter Assay System, according the manufacturer’s instructions on a multilabel plate reader. Data represent mean 6 SD.
*=significantly different from respective controls, P,0.05. (B), VEGF, Bcl-XL, c-Myc, Survivin and Cyclin D1 were detected by qRT-PCR. Data represent
mean 6 SD. *=significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0031067.g003
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were performed in triplicate, and the relative expression of target
mRNA in each sample was normalized with that of mean GAPDH.
PCR primers sequences: GAPDH, forward primer 59- GAG
TCAACGGATTTG GTC GT -39;reverseprimer59- TTG ATT
TTG GAG GGA TCT CG -39; STAT3, forward primer 59- CCT
TTG ACATGG AGT TGA CC -39; reverse primer 59- TAAAAG
TGC CCA GAT TGC TC -39; Cyclin D1, forward primer 59-
TTC AAA TGT GTG CAG AAG GA -39, reverse primer 59-
GGG ATG GTC TCC TTC ATC TT -39; c-Myc, forward primer
59- CGA CGA GAC CTT CAT CAA AA -39, reverse primer 59-
TGC TGT CGT TGA GAG GGT AG -39; Survivin, forward
primer 59- TCC CTG GCT CCT CTA CTG TT -39, reverse
primer 59- TGT CTC CTC ATC CAC CTG AA -39; VEGF,
forward primer 59- AGA CAC ACC CAC CCA CAT AC -39,
reverse primer 59- TGC CAG AGT CTC TCA TCT CC -39;
BclXL forward primer 59- GCT CTC ACT CCC AGT CCA AA -
39, reverse primer 59-GCT GAG GCC ATA AAC AGC TC -39.
Immunofluorescent staining
AsPC-1 and PANC-1 cells were cultured in RPMI medium
containing 10% FBS and treated with EGCG (0, 40, 60 mM) for
24 h. Cells were then fixed with 4% paraformaldehyde and
stained with antibodies against STAT3 (mouse monoclonal IgG1;
Cell Signaling) at 4uC overnight. Cells were washed and again
incubated with anti-mouse-FITC secondary antibody (Sigma)
along with DAPI (0.5 mg/ml). Stained slides were mounted with
mounting medium and visualized under a fluorescence micro-
scope. For better visuality, the color of DAPI was changed from
blue to red. The green color represents the expression of STAT3.
Western blotting analysis
To detect different proteins, AsPC-1 and PANC-1 cells treated
with EGCG (0–60 mM) were washed with PBS and lysed in RIPA
buffer containing 16protease inhibitor cocktail. The lysates were
centrifuged and the supernatant was collected. Protein concentra-
tions were determined using the Bio-Rad Protein Assay (Bio-Rad).
Protein extracts (40 mg) were separated on 12.5% SDS-PAGE.
Transferred membranes were blocked using 5% nonfat dry milk
and incubated overnight with primary antibodies at 1:1,000
dilutions in TBS, followed by secondary antibodies conjugated
with horseradish peroxidase at 1:5,000 dilutions in TBS-Tween 20
for 1 hour at room temperature. Membranes were developed
using ECL Substrate. Protein bands were visualized on X-ray film
using an enhanced chemiluminescence system.
Figure 4. Inhibition of STAT3 enhances the inhibitory effects of EGCG on motility and cell viability of pancreatic cancer cells. (A),
AsPC-1 and PANC-1 were transfected with STAT3 shRNA. The expression of STAT3 was performed by Western blotting. (B), AsPC-1 scratch assay.
AsPC-1 scrambled and STAT3 shRNA cells were cultured in 6 well dishes. The scratch was marked when the dishes were 50% confluent. Pictures were
taken after the cells were treated with EGCG and incubated for 0, 24 and 48 h. (C), Cell viability assay. AsPC-1 and PANC-1 (scrambled and STAT3
shRNA) cells were seeded and treated with EGCG (0, 20, 40, 60 mM). After 72 h of treatment, cell viability was performed by XTT assay. Data represent
mean 6 SD. * or **=significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0031067.g004
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The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA using PRISM statistical analysis software (GrafPad
Software, Inc., San Diego, CA). Significant differences among
groups were calculated at P,0.05.
Results
EGCG inhibits migration and invasion of pancreatic
cancer cells, and induces caspase3 activity
It has been demonstrated that STAT3 plays an important role in
regulatingcell movementbycontrolling cytoskeleton reorganization
and cell adhesion properties [33]. Due to the correlation between
STAT3 and cell movement, we examined the effects of EGCG on
the migration and invasion of AsPC-1 and PANC-1. Cells were
platedin the top of chamber onto the noncoatedmembrane and the
Matrigel coated membrane for migration and invasion detection,
respectively. After the treatments of EGCG, the migrated and
invaded cells were stained and counted. The results show that the
migrated and invaded pancreatic cells reduced in a dose-dependent
manner (Fig. 1A and B). These data suggested that EGCG can
inhibit the migration and invasion of pancreatic cancer cells.
Caspase-3 is a member of the cysteine-aspartic acid protease
(caspase) family and activated in the apoptotic cell both by
extrinsic (death ligand) and intrinsic (mitochondrial) pathways
[34]. EGCG induced caspase-3 activity in a dose dependent
manner in both AsPC-1 and PANC-1 cells, as measured by
fluorometric assay (Fig. 1C). These data suggest that EGCG can
induce apoptosis by activating caspase-3.
EGCG enhances gemcitabine-induced cleavage of
caspase3 and PARP in pancreatic cancer cells
PARP is normally involved in DNA repair, DNA stability, and
other cellular events, and cleaved by members of the caspase
family during early apoptosis; therefore, it is a substrate for caspase
activity and a reliable marker of apoptosis [35]. We next examined
whether EGCG and gemcitabine interact together to cleave
caspase-3 and PARP in AsPC-1 and PANC-1 cells. EGCG and
gemcitabine alone induced cleavage of caspase-3 in both the cell
Figure 5. Effects of STAT3 shRNA on the regulation of cyclin D1, Bcl-XL and c-Myc by EGCG. (A), AsPC-1/scrambled and AsPC-1/STAT3
shRNA cells were treated with or without EGCG (60 mM) for 48 h. The expression of cyclin D1 was measured by q-RT-PCR. Data represent mean 6 SD.
*=significantly different from respective controls, P,0.05. (B), PANC-1/scrambled and PANC-1/STAT3 shRNA cells were treated with or without EGCG
(60 mM) for 48 h. The expression of cyclin D1 was measured by q-RT-PCR. Data represent mean 6 SD. *=significantly different from respective
controls, P,0.05. (C), PANC-1/scrambled and PANC 1/STAT3 shRNA cells were treated with or without EGCG (60 mM) for 48 h. The expression of Bcl-XL
was measured by qRT-PCR. Data represent mean 6 SD. *=significantly different from respective controls, P,0.05. (D), PANC-1/scrambled and PANC-
1/STAT3 shRNA cells were treated with or without EGCG (60 mM) for 48 h. The expression of c-Myc was measured by q-RT-PCR. Data represent mean
6 SD. *=significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0031067.g005
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induced significantly more caspase-3 cleavage than single agent
alone (Fig. 1D). EGCG and gemcitabine alone showed PARP
cleavage in AsPC-1 and PANC-1 cells. By comparison, the
combination of EGCG with gemcitabine resulted in an enhanced
PARP cleavage. These data suggest that EGCG can induce
apoptosis by caspase-3 activation and PARP cleavage.
EGCG inhibits JAK3/STAT3 pathway in pancreatic cancer
We next examined the effects of EGCG on expression of
STAT3, phosphorylation of STAT3 and JAK3, and nuclear
expression of phospho-STAT3 in AsPC-1 and PANC-1 cells. To
examine the effects of EGCG on STAT3 expression, we
performed qRT-PCR analysis (Fig. 2A).
EGCG inhibited the expression of STAT3 mRNA in both
AsPC-1 and PANC-1 cells. We next measured the expression of
total and phosphorylated JAK3 and STAT3 by the Western blot
analysis (Fig. 2B). EGCG inhibited the phosphorylation of both
JAK3 and STAT3 in a dose-dependent manner in AsPC-1 and
PANC-1 cells. Surprisingly, the expression of both JAK3 and
STAT3 was also inhibited by EGCG. These data suggest that
EGCG can inhibit the expression of JAK3 and STAT3, as well as
their post-translation modification.
Since STAT3 is constitutively active in pancreatic cancer cells,
we next examined the effects EGCG on STAT3 expression by
immunofluorescence. As shown in Fig. 2C, EGCG inhibited the
expression of STAT3 (presence of the green color) in a dose-
dependent manner in both the cell lines. These data suggest that
inhibition of apoptosis by EGCG is associated with suppression of
JAK3/STAT3 pathway.
EGCG inhibits STAT3 transcription and expression of
STAT3-regulated genes
STAT3 is considered as an oncogene because it is correlated
with tumorigenesis [7]. Therefore, it is necessary to determine the
effect of EGCG on STAT transcriptional activity. Pancreatic
cancer cells were transfected with pGreen fire1-STAT3 reporter
plasmid and treated with EGCG (0–80 mM). After incubation of
24 h, luciferase activity was determined by reporter assay. As
shown in Fig. 3A, EGCG inhibited STAT3 transcriptional activity
in a dose-dependent manner in pancreatic cancer AsPC-1 and
PANC-1 cells.
Figure 6. EGCG and gemcitabine inhibit cell viability and STAT3 target genes. (A), AsPC-1 and PANC-1 cells were treated with EGCG (0, 20,
40, 60 mM) with or without gemcitabine (0.5 mM) for 72 h. Cell viability was measured by XTT assay. Data represent mean 6 SD. * or **=significantly
different from respective controls, P,0.05. (B), AsPC-1 and PANC-1 cells were treated with EGCG (0, 20, 40, 60 mM) with or without gemcitabine
(0.5 mM) for 72 h. Apoptosis was measured by TUNEL assay. Data represent mean 6 SD. * or **=significantly different from respective controls,
P,0.05. (C), Inhibition of STAT3 target genes by EGCG and gemcitabine. AsPC-1 and PANC-1 cells were treated with EGCG (20 mM) or gemcitabine
(0.5 mM) for 48 h. The expression of VEGF, c-Myc, survivin and cyclin D1was was measured by qRT-PCR. Data represent mean 6 SD. *=significantly
different from respective controls, P,0.05.
doi:10.1371/journal.pone.0031067.g006
STAT3 Signaling in Pancreatic Cancer
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31067Previous studies have shown that STAT3 can regulate the
expression of many gene products involved in proliferation, cell
survival, angiogenesis and anti-apoptosis [7]. For instance, VEGF,
Bcl-XL, c-Myc, Survivin and Cyclin D1 are regulated by STAT3
activation [17,36]. As illustrated in Fig. 3B, STAT3-regulated
genes, c-Myc, Survivin and Cyclin D1 were inhibited by EGCG in
AsPC-1 and PANC-1 cells. EGCG also decreased the expression
of VEGF in AsPC-1 cells, and Bcl-XL in PANC-1 cells. These data
demonstrate that EGCG can inhibit the expression of STAT3-
regulated genes in pancreatic cancer cells. These STAT-3 target
genes have been shown to regulate cell proliferation, cell cycle,
apoptosis and angiogenesis.
Inhibition of STAT3 enhances the inhibitory effects of
EGCGoncellmotilityandviabilityinpancreaticcancer cells
In this work, STAT3 shRNA was used to silence STAT3 gene
expression in AsPC-1 and PANC-1 cells. STAT3 shRNA inhibited
the expression of STAT3 in both AsPC-1 and PANC-1 cells as
demonstrated by the Western blot analysis (Fig. 4A). To examine
the effects of EGCG on pancreatic cancer cells, scratch and cell
viability assays were performed using both scrambled and STAT3
shRNA cells. In scratch assay, the inhibitory effects of EGCG on
the migration of AsPC-1 cells were enhanced by inhibiting STAT3
gene expression (Fig. 4B). EGCG and STAT3 shRNA alone
reduced percent of viable AsPC-1 and PANC-1 cells in a dose-
dependent manner (Fig. 4C). Interestingly, the inhibitory effects of
EGCG on cell viability were further enhanced by STAT3 shRNA
in both the cell lines.
We next examined the effects of STAT3 shRNA on the
regulation of STAT3-target genes by EGCG. EGCG inhibited
the expression of STAT3-regulated gene Cyclin D1 in both AsPC-
1/scrambled and PANC-1/scrambled cells (Fig. 5 and B). STAT3
shRNA completely inhibited the expression of cyclin D1 in both
pancreatic cancer cell lines in the presence or absence of EGCG.
EGCG also inhibited he expression of Bcl-XL and c-Myc in PANC-
1/scrambled cells. Bcl-XL and c-Myc were also inhibited in PANC-
1/STAT3 shRNA cells compared to PANC-1/Scrambled cells.
However, EGCG was unable to further inhibit the expression of
Bcl-XL and c-Myc in PANC-1/STAT3 shRNA cells. These data
suggest that EGCG can regulate pancreatic cancer cell motility and
viability which are associated with STAT3 pathway.
Gemcitabine synergizes with EGCG to inhibit cell viability
and induce apoptosis in pancreatic cancer cells
Gemcitabine has emerged as a popular chemotherapeutic agent
in the treatment of advanced and metastatic pancreatic cancer,
and the benefit of this single-agent is small but significant in the
improvement of median overall survival [19]. To test the effects of
gemcitabine with EGCG on cell viability, pancreatic cancer cells
were treated with gemcitabine (0.5 mM) with or without increasing
concentrations of EGCG (0–60 mM) for 72 hours. As shown in
Fig. 5A, cell viability was inhibited by EGCG and gemcitabine
alone, and the inhibitory effects of gemcitabine on cell viability
were further enhanced by EGCG in these two cell lines (Fig. 6A).
We next examined the interactive effects of EGCG with
gemcitabine on apoptosis in both AsPC-1 and PANC-1 cell lines
(Fig. 6B). EGCG induced apoptosis in both the cell lines in a dose-
dependent manner. Similarly, gemcitabine induced apoptosis in
both AsPC-1 and PANC-1 cells. All the doses of EGCG further
enhanced the effects of gemcitabine on apoptosis. These data
suggest that EGCG can be combined with gemcitabine to treat
pancreatic cancer patients.
We next examined the effects of EGCG and gemcitabine on the
expression of c-Myc and cyclin D1 in AsPC-1 and PANC-1 cells
(Fig. 6C). EGCG and gemcitabine alone inhibited the expression
of VEGF, c-Myc, survivin and cyclin D1was in both the cell lines.
The combination of EGCG and gemcitabine had additive effects
on these target genes. These data suggest that EGCG can enhance
the therapeutic potential of gemcitabine in pancreatic cancer cells
by inhibiting STAT3.
JAK3 inhibitor CP690550 inhibits cell viability in
pancreatic cancer cells
CP690550 is a novel JAK3 inhibitor and expected to target
JAK3, which is expressed generally only in immune cells and is only
bound by gamma-chain-bearing cytokine receptors involved in the
JAK/STAT signaling pathway [37]. We next examined the effects
of CP690550 on cell viability in AsPC-1 and PANC-1 cells (Fig. 7).
CP690550 inhibited cell viability in both the cell lines in a dose-
dependent manner. These data suggest that CP690550 can be a
potential anticancer drug for the treatment of pancreatic cancer.
CP690550 synergizes with EGCG to inhibit cell viability in
pancreatic cancer cells
Since CP690550 induced apoptosis in pancreatic cancer cells,
we next sought to examine the interactive effects of CP690550 and
EGCG on cell viability and apoptosis of pancreatic cancer cells
(Fig. 8). To test the effects of CP690550 with EGCG on cell
viability and apoptosis, pancreatic cancer cells were treated with
CP690550 (0.5 mM) and increasing concentrations of EGCG (0–
60 mM) for 72 hours. As shown in Fig. 8A and B, EGCG and
Figure 7. CP690550 inhibits cell viability of AsPC-1 and PANC-1
cells. (A), AsPC-1 cells were seeded in 96 well plates at 4610
4 cells per
well and treated with CP690550 (0–15 mM) for 72 h. Cell viability was
measured by XTT assay. Data represent mean 6 SD. *=significantly
different from control, P,0.05. (B), PANC-1 cells were seeded in 96 well
plates at 4610
4 cells per well and treated with CP690550 (0–15 mM) for
72 h. Cell viability was measured by XTT assay. Data represent mean 6
SD. *=significantly different from control, P,0.05.
doi:10.1371/journal.pone.0031067.g007
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AsPC-1 and PANC-1 cell lines. Interestingly, EGCG further
enhanced the effects of CP690550 on cell viability and apoptosis in
both the cell lines. These data suggest that CP690550 can be
combined with EGCG to target pancreatic cancer cells.
Since EGCG and CP690550 inhibited cell viability and induced
apoptosis, we next sought to examine their effects on STAT3
target genes. EGCG and CP690550 inhibited the expression
VEGF, c-Myc, survivin and cyclin D1was in both the cell lines
(Fig. 8C). The combination of EGCG and CP690550 had additive
effects on these target genes. These data suggest that EGCG can
enhance the therapeutic potential of CP690550 in pancreatic
cancer cells by inhibiting STAT3.
Discussion
Pancreatic cancer belongs to the group of extremely aggressive
humancancers;conventional treatments havelittleimpact.In2010,
itaccountsforonly3%ofnew cancercasesintheUnitedStates,and
the fourth leading cause of cancer death. Only 6 percent of patients
will survive 5 years after diagnosis [38]. Various factors, which
include its aggressive nature, lack of early screening, absence of
therapeutic targets, and lack of effective treatments, make the
pancreatic cancer become one of the most difficult cancers to treat.
In recent years, the clinicians and cancer scientists have made some
significant advances into the management of the disease, especially
discovery and development of targeted therapeutics [39].
Many oncogenic molecular pathways including EGF/EGFR,
Ras-Raf-MEK, PI3K/Akt, JAK/STAT, p16INK4A/retinoblas-
toma, Smad4/TGF-b, and hedgehog signaling pathways, have
been reported to be involved in the pathogenesis of pancreatic
cancer [40,41,42,43,44,45]. Among them, STAT3 is thought by
many researchers as a suitable therapeutic target for drug
discovery because constitutive activation of STAT3 alone is
sufficient to induce the relevant disease, the inhibition of STAT3
signaling could suppress and reverse the development of relevant
disease, and the molecular mechanism of tumorigenesis caused by
STAT3 pathway has been well defined.
Chemoprevention was first defined by Sporn in 1976 and refers
to the use of natural or synthetic agents to reverse, suppress or
Figure 8. EGCG and CP690550 inhibit cell viability and STAT3 target genes. (A), AsPC-1 and PANC-1 cells were treated with EGCG (0, 20, 40,
60 mM) with or without CP690550 (0.5 mM) for 72 h. Cell viability was measured by XTT assay. Data represent mean 6 SD. * or **=significantly
different from respective controls, P,0.05. (B), AsPC-1 and PANC-1 cells were treated with EGCG (0, 20, 40, 60 mM) with or without CP690550 (0.5 mM)
for 72 h. Apoptosis was measured by TUNEL assay. Data represent mean 6 SD. * or **=significantly different from respective controls, P,0.05. (C),
Inhibition of STAT3 target genes by EGCG and CP690550. AsPC-1 and PANC-1 cells were untreated or treated with EGCG (20 mM) or CP690550
(0.5 mM) for 48 h. The expression of VEGF, c-Myc, survivin and cyclin D1 was measured by qRT-PCR. Data represent mean 6 SD. *=significantly
different from respective controls, P,0.05.
doi:10.1371/journal.pone.0031067.g008
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rationale and promising strategy by several recent epidemiological
studies in preventing cancer in high-risk populations. Because
natural compounds are generally cheaper and safer than synthetic
ones, there is growing interest in the possible therapeutic potential
of natural products against cancer. Many epidemiological,
preclinical, and clinical studies have demonstrated the cancer-
preventive effects of green tea [47,48,49,50]. The chemothera-
peutic and chemopreventive effects of green tea have been
attributed to the polyphenol components, especially EGCG, which
is the most abundant polyphenol in green tea and accounts for
more than 40% of the total polyphenol mixture [51]. In the recent
few decades, it was under intensive investigation by using animal
models of carcinogenesis and cultured tumor cell lines [29,52].
EGCG has demonstrated remarkable chemopreventive and
chemotherapeutic potential against various types of cancers, e.g.
skin, lung, breast, colon, prostate, stomach, and pancreas, by
modulating the intracellular signaling network [30,51,52,53].
In the present study, we provide strong evidence that EGCG
can inhibit cell viability and induce apoptosis of pancreatic cancer
cells. First, we found that the expression and activation of STAT3
were inhibited by EGCG, while the induction of caspase-3 activity
and PARP cleavage were enhanced. Moreover, this compound
also inhibited the invasion and migration of pancreatic cancer
cells, which has been reported to be implicated with STAT3 [54].
These results demonstrate that EGCG has a marked anti-cancer
effect on pancreatic cancer at least in part by the inhibition of
STAT3 signaling pathway. Second, we found that the STAT3
shRNA can alone reduce cell motility and viability of cancer cells.
Furthermore, STAT3 shRNA can enhance the inhibitory effects of
EGCG on cell motility and viability in pancreatic cancer cells,
suggesting that EGCG can influence some other gene/pathway
besides STAT3.
We also found that EGCG could suppress the expression of
STAT3-downstream genes, which include the angiogenic protein
VEGF, cell proliferative Cyclin D1, oncogenic transcription factor
c-Myc, and several anti-apoptotic proteins, including survivin and
Bcl-XL. Some genes are prominent targets for both NF-kB and
STAT3, such as Cyclin D1, Bcl-XL and c-Myc, while survivin is
STAT3-dependant. VEGF is also controlled by STAT3 and might
be indirectly regulated by NF-kB via HIF-1a [55,56,57,58]. The
EGCG-medicated inhibition of Cyclin D1, VEGF, and BclXL
transcription is consistent with previous reports [59,60,61], which
might result from the suppression of EGCG against both the NF-
kB and STAT3 pathways [62]. Similarly, the EGCG inhibition on
Wnt signaling and PI3K/Akt could also contribute to the down-
regulation of cMyc and survivin, respectively [63,64].
Pancreatic cancer is poorly treated by conventional chemother-
apies including gemcitabine due to the profound chemoresistance
through widely expressed HMGA1 [65]. CP690550 (Tasocitinib),
an orally active immunosuppressant, is being developed by Pfizer
for the treatment of inflammatory bowel disease, dry eyes,
rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic
arthritis, and for the prevention of transplant rejection
[21,66,67,68,69,70,71]. CP690550 specifically inhibits JAK3,
which has a pivotal role in cytokine signal transduction that
governs lymphocyte survival, proliferation, differentiation, and
apoptosis. Recent studies have demonstrated the anticancer
activity of CP690550 in various cancers [72]. In this study, we
found that gemcitabine, CP690550 and EGCG alone inhibited
cell viability, induced apoptosis and attenuated STAT3-regulated
gene transcription in AsPC-1 and PANC-1 cells. EGCG further
enhanced the effects of gemcitabine or CP690550 on cell viability,
apoptosis and on the expression of STAT3-target genes. Our
results provide a new application method, in which the use of
EGCG can enhance the therapeutic effects of anticancer drugs
while possibly reducing their side effects.
In conclusion, our findings provide unprecedented insights into
the STAT3 signaling pathway by which EGCG inhibits viability,
invasion and migration, and induces apoptosis in pancreatic
cancer cells. Inhibition of STAT3 by shRNA could suppress
viability of cancer cells, and down-regulate the STAT3-target
genes. Most importantly, EGCG further enhanced the therapeutic
potential of gemcitabine and CP690550 against pancreatic cancer.
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